{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:28:03Z","timestamp":1789450083575,"version":"build-2803163510"},"reference-count":70,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            This study presents detailed analyses of total and specific serum antibody levels among 26 and 24 adult volunteers before vaccination and after the third dose of the meningococcal serogroup B outer membrane vesicle (OMV) vaccines MeNZB and MenBvac, respectively, in a clinical trial in New Zealand (V. Thornton, D. Lennon, K. Rasanathan, J. O'Hallahan, P. Oster, J. Stewart, S. Tilman, I. Aaberge, B. Feiring, H. Nokleby, E. Rosenqvist, K. White, S. Reid, K. Mulholland, M. J. Wakefield, and D. Martin, Vaccine 24:1395-1400, 2006). With the homologous vaccine strains as targets, both vaccines induced significant increases in serum bactericidal and opsonophagocytic activities and in the levels of immunoglobulin G (IgG) to OMV antigens in an enzyme-linked immunosorbent assay (ELISA) and to live meningococci by flow cytometry. They also induced high levels of activity against the heterologous strains, particularly in terms of opsonophagocytic activity and IgG binding to live bacteria. The antibody levels with the homologous and heterologous strains in the four assays showed high and significant positive correlations. Specific IgG binding to 10 major OMV antigens in each vaccine was measured by scanning of immunoblots; ELISAs for two antigens, lipopolysaccharide and\n            <jats:italic>Neisseria<\/jats:italic>\n            surface protein A (NspA), were also performed. Both vaccines elicited significant increases in IgG binding to all homologous and heterologous OMV antigens except NspA. The total IgG band intensity on the blots correlated significantly with the IgG levels determined by the OMV ELISA and flow cytometry. In conclusion, the results of the various immunological assays showed that both OMV vaccines gave rise to high levels of specific and cross-reacting antibodies.\n          <\/jats:p>","DOI":"10.1128\/cvi.00039-07","type":"journal-article","created":{"date-parts":[[2007,5,10]],"date-time":"2007-05-10T00:49:08Z","timestamp":1178758148000},"page":"830-838","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":50,"title":["Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle Vaccines"],"prefix":"10.1128","volume":"14","author":[{"given":"E.","family":"Wedege","sequence":"first","affiliation":[{"name":"Norwegian Institute of Public Health, Department of Bacteriology and Immunology, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway"},{"name":"The Institute of Environmental Science and Research Ltd., Wellington, New Zealand"},{"name":"Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bolstad","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health, Department of Bacteriology and Immunology, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway"},{"name":"The Institute of Environmental Science and Research Ltd., Wellington, New Zealand"},{"name":"Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Aase","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health, Department of Bacteriology and Immunology, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway"},{"name":"The Institute of Environmental Science and Research Ltd., Wellington, New Zealand"},{"name":"Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. K.","family":"Herstad","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health, Department of Bacteriology and Immunology, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway"},{"name":"The Institute of Environmental Science and Research Ltd., Wellington, New Zealand"},{"name":"Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"McCallum","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health, Department of Bacteriology and Immunology, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway"},{"name":"The Institute of Environmental Science and Research Ltd., Wellington, New Zealand"},{"name":"Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rosenqvist","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health, Department of Bacteriology and Immunology, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway"},{"name":"The Institute of Environmental Science and Research Ltd., Wellington, New Zealand"},{"name":"Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Oster","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health, Department of Bacteriology and Immunology, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway"},{"name":"The Institute of Environmental Science and Research Ltd., Wellington, New Zealand"},{"name":"Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Martin","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health, Department of Bacteriology and Immunology, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway"},{"name":"The Institute of Environmental Science and Research Ltd., Wellington, New Zealand"},{"name":"Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.9.3531-3536.1995"},{"key":"e_1_3_2_3_2","first-page":"140","year":"2004","unstructured":"Aase, A. T. K. Herstad, L. M. N\u00e6ss, T. E. Michaelsen, and D. R. Martin. 2004. Abstr. 14th Int. Pathogenic Neisseria Conf., p. 140.","journal-title":"Neisseria"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1046\/j.1365-3083.1998.00319.x","volume":"47","year":"1998","unstructured":"Aase, A., E. A. Hoiby, and T. E. Michaelsen. 1998. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. J. Immunol.47:388-396.","journal-title":"Scand. J. Immunol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0264-410X(02)00774-0","volume":"21","year":"2003","unstructured":"Aase, A., L. M. Naess, R. H. Sandin, T. K. Herstad, F. Oftung, J. Holst, I. L. Haugen, E. A. Hoiby, and T. E. Michaelsen. 2003. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine21:2042-2051.","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0264-410X(94)90314-X","volume":"12","year":"1994","unstructured":"Ala'aldeen, D. A., H. A. Davies, and S. P. Borriello. 1994. Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine12:535-541.","journal-title":"Vaccine"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/mpat.1995.0054","volume":"19","year":"1995","unstructured":"Andersen, S. R., G. Bjune, J. Lyngby, K. Bryn, and E. Jantzen. 1995. Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines. Microb. Pathog.19:159-168.","journal-title":"Microb. Pathog."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","volume":"338","year":"1991","unstructured":"Bjune, G., E. A. Hoiby, J. K. Gronnesby, O. Arnesen, J. Holst Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nokleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Froholm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338:1093-1096.","journal-title":"Lancet"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","year":"2005","unstructured":"Borrow, R., P. Balmer, and E. Miller. 2005. Meningococcal surrogates of protection\u2014serum bactericidal antibody activity. Vaccine23:2222-2227.","journal-title":"Vaccine"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.4.2222-2231.2005"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","volume":"13","year":"1995","unstructured":"Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, and J. Mays. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15-P1.3) outer-membrane protein vaccine in Iquique, Chile. Vaccine13:821-829.","journal-title":"Vaccine"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/S0264-410X(03)00033-1","volume":"21","year":"2003","unstructured":"Clarke, S. C., M. A. Diggle, P. Molling, M. Unemo, and P. Olcen. 2003. Analysis of PorA variable region 3 in meningococci: implications for vaccine policy? Vaccine.21:2468-2473.","journal-title":"Vaccine."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1046\/j.1432-1033.2002.03228.x","volume":"269","year":"2002","unstructured":"de Jonge, M. I., M. P. Bos, H. J. Hamstra, W. Jiskoot, P. van Ulsen, J. Tommassen, L. van Alphen, and L. P. van der Ley. 2002. Conformational analysis of opacity proteins from Neisseria meningitidis. Eur. J. Biochem.269:5215-5223.","journal-title":"Eur. J. Biochem."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","volume":"340","year":"1992","unstructured":"de Moraes, J. C., B. A. Perkins, M. C. C. Camargo, N. T. R. Hidalgo, H. A. Barbosa, C. T. Sacchi, I. M. L. Gral, V. L. Gattas, H. D. Vasconcelos, B. D. Plikaytis, J. D. Wenger, and C. V. Broome. 1992. Protective efficacy of a serogroup B meningococcal vaccine in Sao-Paulo, Brazil. Lancet340:1074-1078.","journal-title":"Lancet"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.2.832-837.2005"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.2.838-842.2005"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1017\/S0950268805004954","volume":"134","year":"2006","unstructured":"Dyet, K. H., and D. R. Martin. 2006. Clonal analysis of the serogroup B meningococci causing New Zealand's epidemic. Epidemiol. Infect.134:377-383.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/pmic.200500164","volume":"6","year":"2006","unstructured":"Ferrari, G., I. Garaguso, J. Adu-Bobie, F. Doro, A. R. Taddei, A. Biolchi, B. Brunelli, M. M. Giuliani, M. Pizza, N. Norais, and G. Grandi. 2006. Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics6:1856-1866.","journal-title":"Proteomics"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00466-06"},{"key":"e_1_3_2_20_2","first-page":"177","volume":"43","year":"1983","unstructured":"Frasch, C., G. Coetzee, J. M. Zahadrik, H. A. Feldman, and H. J. Kornhoof. 1983. Development and evaluation of group B serotype 2 protein vaccines: report of a group B field trial. Med. Trop. (Marseille)43:177-180.","journal-title":"Med. Trop. (Marseille)"},{"key":"e_1_3_2_21_2","first-page":"67","volume":"14","year":"1991","unstructured":"Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Froholm, A. K. Lindbak, B. Mogster, E. Namork, U. Rye, G. Stabbetorp, R. Winsnes, A. Aase, and O. Closs. 1991. Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann.14:67-79.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0928-8244(97)00109-0","volume":"20","year":"1998","unstructured":"Gomez, J. A., M. T. Criado, and C. M. Ferreiros. 1998. Bactericidal activity of antibodies elicited against the Neisseria meningitidis 37-kDa ferric binding protein (FbpA) with different adjuvants. FEMS Immunol. Med. Microbiol.20:79-86.","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.vaccine.2006.08.001","volume":"25","year":"2007","unstructured":"Halperin, S. A., J. M. Langley, B. Smith, P. Wunderli, L. Kaufman, A. Kimura, and D. Martin. 2007. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine25:450-457.","journal-title":"Vaccine"},{"key":"e_1_3_2_24_2","first-page":"147","volume":"14","year":"1991","unstructured":"Hoiby, E. A., E. Rosenqvist, L. O. Froholm, G. Bjune, B. Feiring, H. Nokleby, and E. Ronnild. 1991. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann.14:147-155.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_25_2","unstructured":"A \u2018taylor made\u2019 vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. 2006"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","volume":"23","year":"2005","unstructured":"Holst, J., B. Feiring, L. M. Naess, G. Norheim, P. Kristiansen, E. A. Hoiby, K. Bryn, P. Oster, P. Costantino, M. K. Taha, J. M. Alonso, D. A. Caugant, E. Wedege, I. S. Aaberge, R. Rappuoli, and E. Rosenqvist. 2005. The concept of \u201ctailor-made,\u201d protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine23:2202-2205.","journal-title":"Vaccine"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vaccine.2005.07.056","volume":"24","year":"2006","unstructured":"Humphries, H. E., J. N. Williams, R. Blackstone, K. A. Jolley, H. M. Yuen, M. Christodoulides, and J. E. Heckels. 2006. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis. Vaccine24:36-44.","journal-title":"Vaccine"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1099\/00222615-43-5-335","volume":"43","year":"1995","unstructured":"Idanpaan-Heikkila, I., E. A. Hoiby, P. Chattopadhyay, U. Airaksinen, T. M. Michaelsen, and E. Wedege. 1995. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J. Med. Microbiol.43:335-343.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0005-2736(00)00155-3","volume":"1464","year":"2000","unstructured":"Jansen, C., A. Wiese, L. Reubsaet, N. Dekker, H. de Cock, U. Seydel, and J. Tommassen. 2000. Biochemical and biophysical characterization of in vitro folded outer membrane porin PorA of Neisseria meningitidis. Biochim. Biophys. Acta1464:284-298.","journal-title":"Biochim. Biophys. Acta"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1099\/00221287-145-11-3013","volume":"145","year":"1999","unstructured":"Jennings, M. P., Y. N. Srikhanta, E. R. Moxon, M. Kramer, J. T. Poolman, B. Kuipers, and P. van der Ley. 1999. The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. Microbiology145(Pt 11):3013-3021.","journal-title":"Microbiology"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.micinf.2006.04.011","volume":"8","year":"2006","unstructured":"Kortekaas, J., S. A. Muller, P. Ringler, M. Gregorini, V. E. Weynants, L. Rutten, M. P. Bos, and J. Tommassen. 2006. Immunogenicity and structural characterisation of an in vitro folded meningococcal siderophore receptor (FrpB, FetA). Microbes Infect.8:2145-2153.","journal-title":"Microbes Infect."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.vaccine.2006.07.016","volume":"25","year":"2007","unstructured":"Kortekaas, J., A. Pettersson, J. van der Biezen, V. E. Weynants, P. van der Ley, J. Poolman, M. P. Bos, and J. Tommassen. 2007. Shielding of immunogenic domains in Neisseria meningitidis FrpB (FetA) by the major variable region. Vaccine25:72-84.","journal-title":"Vaccine"},{"key":"e_1_3_2_33_2","first-page":"268","year":"2002","unstructured":"Kristiansen, P. A., I. S. Aaberge, K. M\u00f8yner, L. M. N\u00e6ss, K. Bryn, K. Nord, A. G. Skryten, E. Namork, E. Rosenqvist, and K. Harbak. 2002. Abstr. 13th Int. Pathogenic Neisseria Conf., p. 268.","journal-title":"Neisseria"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-1759(84)90080-2","volume":"67","year":"1984","unstructured":"Mandrell, R. E., and W. D. Zollinger. 1984. Use of a zwitterionic detergent for the restoration of the antibody-binding capacity of electroblotted meningococcal outer membrane proteins. J. Immunol. Methods67:1-11.","journal-title":"J. Immunol. Methods"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1084\/jem.185.7.1173","volume":"185","year":"1997","unstructured":"Martin, D., N. Cadieux, J. Hamel, and B. R. Brodeur. 1997. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med.185:1173-1183.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.vaccine.2005.01.070","volume":"23","year":"2005","unstructured":"Martin, D., L. McCallum, A. Glennie, N. Ruijne, P. Blatchford, J. O'Hallahan, and P. Oster. 2005. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine23:2218-2221.","journal-title":"Vaccine"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.4.486-491.2006"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2958.1993.tb01141.x","volume":"7","year":"1993","unstructured":"McGuinness, B. T., P. R. Lambden, and J. E. Heckels. 1993. Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology. Mol. Microbiol.7:505-514.","journal-title":"Mol. Microbiol."},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/S0264-410X(00)00324-8","volume":"19","year":"2001","unstructured":"Michaelsen, T. E., A. Aase, J. Kolberg, E. Wedge, and E. Rosenqvist. 2001. PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria. Vaccine19:1526-1533.","journal-title":"Vaccine"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.10.4419-4424.1994"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.11.5664-5675.1999"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0264-410X(98)00259-X","volume":"17","year":"1999","unstructured":"Naess, L. M., T. Aarvak, A. Aase, F. Oftung, E. A. Hoiby, R. Sandin, and T. E. Michaelsen. 1999. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine17:754-764.","journal-title":"Vaccine"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1016\/j.vaccine.2005.02.021","volume":"23","year":"2005","unstructured":"Norheim, G., A. Aase, D. A. Caugant, E. A. Hoiby, E. Fritzsonn, T. Tangen, P. Kristiansen, U. Heggelund, and E. Rosenqvist. 2005. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine23:3762-3774.","journal-title":"Vaccine"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.vaccine.2005.01.061","volume":"23","year":"2005","unstructured":"O'Hallahan, J., D. Lennon, P. Oster, R. Lane, S. Reid, K. Mulholland, J. Stewart, L. Penney, T. Percival, and D. Martin. 2005. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine23:2197-2201.","journal-title":"Vaccine"},{"key":"e_1_3_2_45_2","first-page":"64","year":"2002","unstructured":"Rosenqvist, E., K. Bryn, K. Harbak, J. Holst, E. A. H\u00f8iby, P. Kristiansen, H. Lange, D. Martin, K. M\u00f8yner, K. Nord, L. M. N\u00e6ss, A. G. Skryten, I. Aaberge, A. Aase, and H. N\u00f8kleby. 2002. Abstr. 13th Int. Pathogenic Neisseria Conf., p. 64.","journal-title":"Neisseria"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/infdis\/167.5.1065","volume":"167","year":"1993","unstructured":"Rosenqvist, E., E. A. Hoiby, E. Wedege, B. Kusecek, and M. Achtman. 1993. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis.167:1065-1073.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.3.1267-1276.1999"},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/infdis\/155.6.1266","volume":"155","year":"1987","unstructured":"Ross, S. C., P. J. Rosenthal, H. M. Berberich, and P. Densen. 1987. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis.155:1266-1275.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00038-06"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1099\/00222615-41-4-236","volume":"41","year":"1994","unstructured":"Scholten, R. J., B. Kuipers, H. A. Valkenburg, J. Dankert, W. D. Zollinger, and J. T. Poolman. 1994. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med. Microbiol.41:236-243.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_52_2","first-page":"195","volume":"14","year":"1991","unstructured":"Sierra, G. V., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14:195-207.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/mic.0.26131-0","volume":"149","year":"2003","unstructured":"Thompson, E. A., I. M. Feavers, and M. C. Maiden. 2003. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology149:1849-1858.","journal-title":"Microbiology"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","volume":"24","year":"2006","unstructured":"Thornton, V., D. Lennon, K. Rasanathan, J. O'Hallahan, P. Oster, J. Stewart, S. Tilman, I. Aaberge, B. Feiring, H. Nokleby, E. Rosenqvist, K. White, S. Reid, K. Mulholland, M. J. Wakefield, and D. Martin. 2006. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine24:1395-1400.","journal-title":"Vaccine"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1016\/j.vaccine.2005.05.005","volume":"23","year":"2005","unstructured":"Toropainen, M., L. Saarinen, E. Wedege, K. Bolstad, P. H. Makela, and H. Kayhty. 2005. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines. Vaccine23:4821-4833.","journal-title":"Vaccine"},{"key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0003-2697(82)90673-X","volume":"119","year":"1982","unstructured":"Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem.119:115-119.","journal-title":"Anal. Biochem."},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1099\/13500872-142-11-3269","volume":"142","year":"1996","unstructured":"van der Ley, P., J. van der Biezen, R. Sutmuller, P. Hoogerhout, and J. T. Poolman. 1996. Sequence variability of FrpB, a major iron-regulated outer-membrane protein in the pathogenic neisseriae. Microbiology142(Pt 11):3269-3274.","journal-title":"Microbiology"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.7.2745-2751.1996"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.4.1650-1655.2003"},{"key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/hv.1.2.1651","volume":"1","year":"2005","unstructured":"Vipond, C., J. X. Wheeler, I. M. Feavers, J. Suker, and C. Jones. 2005. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry. Hum. Vaccine1:80-84.","journal-title":"Hum. Vaccine"},{"key":"e_1_3_2_61_2","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1002\/pmic.200500821","volume":"6","year":"2006","unstructured":"Vipond, C., J. Suker, C. Jones, C. Tang, I. M. Feavers, and J. X. Wheeler. 2006. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98\/254. Proteomics6:3400-3413.","journal-title":"Proteomics"},{"key":"e_1_3_2_62_2","first-page":"275","year":"2001","unstructured":"Wedege, E. 2001. Immunoblot analysis of sera from patients and vaccinees, p. 275-288. In A. J. Pollard and M. C. J. Maiden (ed.), Meningococcal vaccines: methods and protocols. Humana Press, Totowa, NJ.","journal-title":"Meningococcal vaccines: methods and protocols"},{"key":"e_1_3_2_63_2","first-page":"196","year":"2004","unstructured":"Wedege, E., I. Aaberge, K. Bolstad, E. Fritzs\u00f8nn, U. Heggelund, L. McCallum, L. M. N\u00e6ss, E. Rosenqvist, and D. Martin. 2004. Abstr. 14th Int. Pathogenic Neisseria Conf., p. 196.","journal-title":"Neisseria"},{"key":"e_1_3_2_64_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0022-1759(88)90381-X","volume":"113","year":"1988","unstructured":"Wedege, E., K. Bryn, and L. O. Froholm. 1988. Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents. J. Immunol. Methods113:51-59.","journal-title":"J. Immunol. Methods"},{"key":"e_1_3_2_65_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1099\/00222615-38-1-23","volume":"38","year":"1993","unstructured":"Wedege, E., R. Dalseg, D. A. Caugant, J. T. Poolman, and L. O. Froholm. 1993. Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins. J. Med. Microbiol.38:23-28.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.51.2.571-578.1986"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.7.3223-3231.1998"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.7.3775-3781.2003"},{"key":"e_1_3_2_69_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0003-2697(87)90048-0","volume":"160","year":"1987","unstructured":"Wu, L. H., C. M. Tsai, and C. E. Frasch. 1987. A method for purification of bacterial R-type lipopolysaccharides (lipooligosaccharides). Anal. Biochem.160:281-289.","journal-title":"Anal. Biochem."},{"key":"e_1_3_2_70_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","volume":"126","year":"1972","unstructured":"Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis.126:514-521.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_71_2","unstructured":"Pathogenic Neissseria Conf. 2006"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00039-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00039-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:38:42Z","timestamp":1627591122000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00039-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1128\/CVI.00039-07"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00039-07","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7]]},"assertion":[{"value":"2007-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-04-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}